These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 21924613

  • 1. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain.
    Meyers MJ, Long SA, Pelc MJ, Wang JL, Bowen SJ, Schweitzer BA, Wilcox MV, McDonald J, Smith SE, Foltin S, Rumsey J, Yang YS, Walker MC, Kamtekar S, Beidler D, Thorarensen A.
    Bioorg Med Chem Lett; 2011 Nov 01; 21(21):6545-53. PubMed ID: 21924613
    [Abstract] [Full Text] [Related]

  • 2. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 1: identification of 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane as lead scaffolds.
    Meyers MJ, Long SA, Pelc MJ, Wang JL, Bowen SJ, Walker MC, Schweitzer BA, Madsen HM, Tenbrink RE, McDonald J, Smith SE, Foltin S, Beidler D, Thorarensen A.
    Bioorg Med Chem Lett; 2011 Nov 01; 21(21):6538-44. PubMed ID: 21924614
    [Abstract] [Full Text] [Related]

  • 3. Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase.
    Keith JM, Jones WM, Pierce JM, Seierstad M, Palmer JA, Webb M, Karbarz MJ, Scott BP, Wilson SJ, Luo L, Wennerholm ML, Chang L, Brown SM, Rizzolio M, Rynberg R, Chaplan SR, Breitenbucher JG.
    Bioorg Med Chem Lett; 2014 Feb 01; 24(3):737-41. PubMed ID: 24433863
    [Abstract] [Full Text] [Related]

  • 4. Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.
    Gustin DJ, Ma Z, Min X, Li Y, Hedberg C, Guimaraes C, Porter AC, Lindstrom M, Lester-Zeiner D, Xu G, Carlson TJ, Xiao S, Meleza C, Connors R, Wang Z, Kayser F.
    Bioorg Med Chem Lett; 2011 Apr 15; 21(8):2492-6. PubMed ID: 21392988
    [Abstract] [Full Text] [Related]

  • 5. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
    Russo R, Loverme J, La Rana G, Compton TR, Parrott J, Duranti A, Tontini A, Mor M, Tarzia G, Calignano A, Piomelli D.
    J Pharmacol Exp Ther; 2007 Jul 15; 322(1):236-42. PubMed ID: 17412883
    [Abstract] [Full Text] [Related]

  • 6. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain.
    Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, Young T, Wren P, Zhang Y, Swaney S, Van Becelaere K, Blankman JL, Nomura DK, Bhattachar SN, Stiff C, Nomanbhoy TK, Weerapana E, Johnson DS, Cravatt BF.
    J Pharmacol Exp Ther; 2011 Jul 15; 338(1):114-24. PubMed ID: 21505060
    [Abstract] [Full Text] [Related]

  • 7. Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
    Kono M, Matsumoto T, Imaeda T, Kawamura T, Fujimoto S, Kosugi Y, Odani T, Shimizu Y, Matsui H, Shimojo M, Kori M.
    Bioorg Med Chem; 2014 Feb 15; 22(4):1468-78. PubMed ID: 24440478
    [Abstract] [Full Text] [Related]

  • 8. Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
    Vincent F, Nguyen MT, Emerling DE, Kelly MG, Duncton MA.
    Bioorg Med Chem Lett; 2009 Dec 01; 19(23):6793-6. PubMed ID: 19850474
    [Abstract] [Full Text] [Related]

  • 9. Synthesis, SAR study, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase (FAAH) inhibitors.
    Kono M, Matsumoto T, Kawamura T, Nishimura A, Kiyota Y, Oki H, Miyazaki J, Igaki S, Behnke CA, Shimojo M, Kori M.
    Bioorg Med Chem; 2013 Jan 01; 21(1):28-41. PubMed ID: 23218778
    [Abstract] [Full Text] [Related]

  • 10. Structure based design of novel irreversible FAAH inhibitors.
    Wang JL, Bowen SJ, Schweitzer BA, Madsen HM, McDonald J, Pelc MJ, Tenbrink RE, Beidler D, Thorarensen A.
    Bioorg Med Chem Lett; 2009 Oct 15; 19(20):5970-4. PubMed ID: 19765986
    [Abstract] [Full Text] [Related]

  • 11. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
    Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, Lund ET, Nugent RA, Nomanbhoy TK, Alexander JP, Cravatt BF.
    Biochemistry; 2007 Nov 13; 46(45):13019-30. PubMed ID: 17949010
    [Abstract] [Full Text] [Related]

  • 12. High-throughput screening for the discovery of inhibitors of fatty acid amide hydrolase using a microsome-based fluorescent assay.
    Wang Y, Ramirez F, Krishnamurthy G, Gilbert A, Kadakia N, Xu J, Kalgaonkar G, Ramarao MK, Edris W, Rogers KE, Jones PG.
    J Biomol Screen; 2006 Aug 13; 11(5):519-27. PubMed ID: 16760367
    [Abstract] [Full Text] [Related]

  • 13. Latest advances in the discovery of fatty acid amide hydrolase inhibitors.
    Bisogno T, Maccarrone M.
    Expert Opin Drug Discov; 2013 May 13; 8(5):509-22. PubMed ID: 23488865
    [Abstract] [Full Text] [Related]

  • 14. Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).
    Lodola A, Castelli R, Mor M, Rivara S.
    Expert Opin Ther Pat; 2015 May 13; 25(11):1247-66. PubMed ID: 26413912
    [Abstract] [Full Text] [Related]

  • 15. Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).
    Le Bourdonnec B, Windh RT, Leister LK, Zhou QJ, Ajello CW, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE.
    J Med Chem; 2009 Sep 24; 52(18):5685-702. PubMed ID: 19694468
    [Abstract] [Full Text] [Related]

  • 16. Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
    Hart T, Macias AT, Benwell K, Brooks T, D'Alessandro J, Dokurno P, Francis G, Gibbons B, Haymes T, Kennett G, Lightowler S, Mansell H, Matassova N, Misra A, Padfield A, Parsons R, Pratt R, Robertson A, Walls S, Wong M, Roughley S.
    Bioorg Med Chem Lett; 2009 Aug 01; 19(15):4241-4. PubMed ID: 19515560
    [Abstract] [Full Text] [Related]

  • 17. Discovery of a Potent, Long-Acting, and CNS-Active Inhibitor (BIA 10-2474) of Fatty Acid Amide Hydrolase.
    Kiss LE, Beliaev A, Ferreira HS, Rosa CP, Bonifácio MJ, Loureiro AI, Pires NM, Palma PN, Soares-da-Silva P.
    ChemMedChem; 2018 Oct 22; 13(20):2177-2188. PubMed ID: 30113139
    [Abstract] [Full Text] [Related]

  • 18. 1-(3-biaryloxy-2-oxopropyl)indole-5-carboxylic acids and related compounds as dual inhibitors of human cytosolic phospholipase A2α and fatty acid amide hydrolase.
    Zahov S, Drews A, Hess M, Schulze Elfringhoff A, Lehr M.
    ChemMedChem; 2011 Mar 07; 6(3):544-9. PubMed ID: 21259444
    [Abstract] [Full Text] [Related]

  • 19. In vitro and in vivo pharmacological characterization of ASP8477: A novel highly selective fatty acid amide hydrolase inhibitor.
    Watabiki T, Tsuji N, Kiso T, Ozawa T, Narazaki F, Kakimoto S.
    Eur J Pharmacol; 2017 Nov 15; 815():42-48. PubMed ID: 29017758
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis, and in vitro evaluation of carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl-(3-hydroxyphenyl)-methanones as novel fatty acid amide hydrolase inhibitors.
    Myllymäki MJ, Saario SM, Kataja AO, Castillo-Melendez JA, Nevalainen T, Juvonen RO, Järvinen T, Koskinen AM.
    J Med Chem; 2007 Aug 23; 50(17):4236-42. PubMed ID: 17665899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.